Involvement of CYP2D1 in the metabolism of carteolol by male rat liver microsomes

References

• ALVAN, G., BECHTEL, P., ISELIUS, L. and GUNDERT -REEvn,, U., 1990, Hydroxylation polymorphism sof debrisoquine and mephenytoin in European populations. European Journal of Clinical Phar-macology, 39, 533–537.
   Google Scholar
• BRADY, J. F., XIAO, F., WANG, M.-H., LI, Y., NING, S. M., GAPAC, J. M. and YANG, C. S., 1991, Effects of disulfiram on hepatic P450 IIE1, other microsomal enzymes, and hepatotoxicity in rats. Toxicology and Applied Pharmacology, 108, 366–373.
   Google Scholar
• BROSEN, K., 1990, Recent developments in hepatic drug oxidation: Implicationsfor clinical pharmaco-kinetics. Clinical Pharmacokinetic s, 18, 220–239.
   PubMed Web of Science ®Google Scholar
• CHANG, T., LEVINE, M. and BELLWARD, G. D., 1992, Selective inhibition of rat hepatic microsomal cytochromeP-450. II. Effect of the in vitro administrationof cimetidine. jounta/ of Pharmacology and Experimental Therapeutics, 260, 1450–1455.
   PubMed Web of Science ®Google Scholar
• CORREIA, M. A., 1995, Rat and human liver cytochromes P450: substrate and inhibitor specificities and functional markers. In Cytochronte P450: Structure, Mechanism, and Biochemistry, 2nd edn, edited by P. R. Ortiz De Montellano (New York: Plenum Press), pp. 607–630.
   Google Scholar
• DIXON, M., 1953, The determ ination of enzyme inhibitor constants. Biochemical Journal, 55, 170–171.
   PubMed Web of Science ®Google Scholar
• GONZALEZ, F. J., SKODA, R. C., KIMURA, S., UMENO, M., ZANGER, U. M., NEBERT, D. W., GELBOIN, H. V., HARDWICK, J. P. and MEYER, U. A., 1988, Characterizaticn of the common genetic defect in humans deficient in debrisoquine metabolism. Nature, 331, 442–446.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., KIM, D.-H. and IWASAKI, M., 1991, Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology, 4, 168–179.
   Google Scholar
• IMAOKA, S., TERANO, Y. and FUNAE, Y., 1990, Changes in the amountof cytochromeP450s in rat hepatic microsomes with starvation. Archives of Biochemistry and Biophysics, 278, 168–178.
   PubMed Web of Science ®Google Scholar
• ISOGAI M S HIMADA, N., KAMATAKI, T., IMAOKA S. and FUNAE, Y., 1993, Changes in the amounts of cytochromes P450 in rat hepatic microsomes produced by cyclosporin A. Xerzobiotica, 23, 799–807.
   Google Scholar
• KANEKO, Y., 1977, Clinicaleffect of carteolol hydrochlorideon various tachycardiaand arrhythmias (II). Therapeutic effect at low dosage levels. journal of New Remedies and Clinics, 26, 113–122.
   Google Scholar
• KOBAYASHI, S., MURRAY, S., WATSON, D., SESARDIC, D., DAvrEs, D. S. and BOOBIS, A. R., 1989, The specificity of inhibitionof debrisoquine4-hydroxylaseactivity by quinidineand quinine in the rat is the inverse of that in man. Biochemical Pharmacology, 38, 2795–2799.
   PubMed Web of Science ®Google Scholar
• KOYMANS, L., VERMEULEN, N. P. E., VAN ACKER, S. A. B. E., TE KOPPELE J. M., HEYKANTS J. J. P., LAVRIJSEN, K., MEULDERMANS W. and DEN KELDER, G. M. D.-0., 1992, A predictive model for substrates of cytochromeP450-D ebrisoquine(2D 6). Chemical Research in Toxicology, 5, 211–219.
   Google Scholar
• LENNARD, M. S., JACKSON, P. R., FREESTONE, S., TUCICER, G. T., RAMSAY, L. E. and WOOD, H. F.,1984, The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamie of propranolol. British Journal of Clinical Pharmacology, 17, 679–685.
   PubMed Web of Science ®Google Scholar
• MASUBUCHI, Y., KAGIMOTO, N., NARIMATSU, S., FUJITA, S. and Suzum, T., 1993, Regioselective contribution of the cytochrome P-450 2D subfamily to propranolol metabolism in rat liver microsomes. Drug Metabolism and Disposition, 21, 1012–1016.
   PubMedGoogle Scholar
• MATSUNAGA, E., ZANGER, U. M., HARDWICK, J. P., GELBOIN, H. V., MEYER, U. A. and GONZALEZ, F. J., 1989, The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. Biochemistry, 28, 7349–7355.
   PubMed Web of Science ®Google Scholar
• MORI, H., KIDO, M., MURAKAMI, N., MORITA, S., KOHRI, H., NAKAGAWA, K., UNO, T. and ISHIHARA T., 1977, Metabolic fate of carteolol hydrochloride [5-(3-tert-butylamino-2-hydroxy-propoxy)-3,4-dihydrocarbostyril hydrochloride, OPC -1085], a new fl-blocker. V. Identificationof metabo-lites in rat, dog and human. jounta/ of the Pharmaceutical Society of japan, 97, 350–358.
   Google Scholar
• NAKANO, T. and SAWADA, J., 1976, Hypotensive effect of carteolol hydrochloride (OPC-1085) in hypertension. journa/ of New Remedies and Clinics, 25, 1451–1457.
   Google Scholar
• NEVILLE, C. F., NINOMIYA, S., SHEVIADA, N., KAMATAKI, T., IMAOKA, S. and FUNAE, Y., 1993, Characterizaticn of specificcytochromeP450 enzymesresponsiblefor the metabolismof diazepam in hepatic microsomes of adult male rats. Biochemical Pharmacology, 45, 59–65.
   PubMed Web of Science ®Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxidebinding pigmentof liver microsomes. I. Evidence for its hemoprotein structure. journal of Biological Chemistry, 239, 2370–2378.
   PubMed Web of Science ®Google Scholar
• RAGHURAM, T. C., KOSHAKJI, R. P., WILKINSON, G. R. and WOOD, A. J. J., 1984, Polym orphicability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade. Clinical Pharmacology and Therapeutics, 36, 51–56.
   PubMed Web of Science ®Google Scholar
• SESARDIC D BOOBIS, A., MURRAY, B., MURRAY, S., SEGURA, J., DE LA TORRE, R. and DAVIES, D., 1990, Furafylline is a potent and selective inhibitor of cytochrome P450 1A2 in man. British journal of Clinical Pharmacology, 29, 651–663.
   PubMedGoogle Scholar
• SMITH, D. A., 1991, Species diff erences in metabolism and pharmacokinetics. Drug Metabolism Reviews, 23, 355–373.
   PubMed Web of Science ®Google Scholar
• SONDERFAN, A. J., ARLOTTO, M. P., DUTTON, D. R., MCMILLEN, S. K. and PARKINSON, A., 1987, Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Archives of Biochemistry and Biophysics, 255, 27–41.
   PubMed Web of Science ®Google Scholar
• SUZUKI, T., NARIMATSU, S., FUJITA, S., MASUBUCHI, Y., UMEDA, S., IMAOKA, S. and FUNAE, Y., 1992, Purification and characterization of a cytochrome P-450 isozyme catalyzing bunitrolol 4-hydroxylation in liver microsomes of male rats. Drug Metabolism and Disposition, 20, 367–373.
   PubMed Web of Science ®Google Scholar
• TOI, K. and YABUKI, 5.,1977, Treatmentwith carteololin various types of anginapectoris, mostly angina of effort. journal of New Remedies and Clinics, 26, 713–719.
   Google Scholar
• WARD, S. A., WALLE, T., WALLE, U. K ., WILKINSON, G. R. and BRANCH, R. A., 1989, Propranolol's metabolism is determined by both mephenytoin and debrisoquinhydroxylase activities. Clinical Pharmacology and Therapeutics, 45, 72–79.
   Google Scholar
• WRIGHTON, S. A., MAUREL, P., SCHUETZ E. G., WATKINS, P. B., YOUNG, B. and GUZELIAN, P. S., 1985, Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-45 Op. Biochemistry, 24, 2171–2178.
   Google Scholar